CAW
JAZZ icon

Cornerstone Advisors (Washington)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-43
Closed -$6K – 1107
2019
Q2 		$6K Buy
43
+23
+115% +$3.09K ﹤0.01% 888
2019
Q1 		$3K Sell
20
-271
-93% -$35.3K ﹤0.01% 915
2018
Q4 		$36K Buy
291
+13
+5% +$1.93K 0.01% 374
2018
Q3 		$47K Hold
278
– – 0.03% 329
2018
Q2 		$48K Buy
+278
New +$45.4K 0.03% 306
2016
Q4 		– Sell
-252
Closed -$31K – 960
2016
Q3 		$31K Hold
252
– – 0.03% 355
2016
Q2 		$36K Buy
252
+31
+14% +$4.57K 0.04% 191
2016
Q1 		$29K Sell
221
-83
-27% -$10.3K 0.03% 230
2015
Q4 		$43K Sell
304
-4
-1% -$554 0.05% 200
2015
Q3 		$41K Buy
+308
New +$53K 0.04% 203

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Cornerstone Advisors (Washington)'s JAZZ Position: Q3 2019 in Review

Cornerstone Advisors (Washington) sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2019, closing a stake of 43 shares — an estimated $6K sold.

Cornerstone Advisors (Washington) first reported a position in JAZZ in Q3 2015 and held it in 10 quarters. The position peaked at $48K in Q2 2018. 406 funds tracked by Wall St. Rank hold JAZZ as of Q3 2019.

  • Cornerstone Advisors (Washington) reported no remaining Jazz Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Cornerstone Advisors (Washington) sold 43 Jazz Pharmaceuticals shares in Q3 2019, an estimated $6K.
  • Cornerstone Advisors (Washington) first reported a position in Jazz Pharmaceuticals in Q3 2015 and held it in 10 quarters.
  • Cornerstone Advisors (Washington)'s Jazz Pharmaceuticals position peaked at $48K in Q2 2018.
  • 406 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2019.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2019, filed 23 Oct 2019.